200 related articles for article (PubMed ID: 15100502)
1. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
[TBL] [Abstract][Full Text] [Related]
2. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
3. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
4. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
6. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
8. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
9. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
12. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
[TBL] [Abstract][Full Text] [Related]
13. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?
Amthauer H; Ruf J; Böhmig M; Lopez-Hänninen E; Rohlfing T; Wernecke KD; Plöckinger U; Gutberlet M; Lemke AJ; Steinmüller T; Wiedenmann B; Felix R
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):342-8. PubMed ID: 14652697
[TBL] [Abstract][Full Text] [Related]
15. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
Kumbasar B; Kamel IR; Tekes A; Eng J; Fishman EK; Wahl RL
Abdom Imaging; 2004; 29(6):696-702. PubMed ID: 15162235
[TBL] [Abstract][Full Text] [Related]
16. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
17. Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.
Biliotti G; Martini F; Vaggelli L; Messerini L; Colagrande S; Pupi A; Seghi P
Tumori; 2006; 92(2):170-4. PubMed ID: 16724698
[TBL] [Abstract][Full Text] [Related]
18. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
19. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
[TBL] [Abstract][Full Text] [Related]
20. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours.
Rodrigues M; Gabriel M; Heute D; Putzer D; Griesmacher A; Virgolini I
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1796-802. PubMed ID: 18425512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]